Search
Search Results
-
Assessment of cerebral drug occupancy in humans using a single PET-scan: A [11C]UCB-J PET study
PurposeHere, we evaluate a PET displacement model with a Single-step and Numerical solution in healthy individuals using the synaptic vesicle...
-
Drug characteristics derived from kinetic modeling: combined 11C-UCB-J human PET imaging with levetiracetam and brivaracetam occupancy of SV2A
BackgroundAntiepileptic drugs, levetiracetam (LEV) and brivaracetam (BRV), bind to synaptic vesicle glycoprotein 2A (SV2A). In their anti-seizure...
-
The regional pattern of age-related synaptic loss in the human brain differs from gray matter volume loss: in vivo PET measurement with [11C]UCB-J
PurposeAging is a major societal concern due to age-related functional losses. Synapses are crucial components of neural circuits, and synaptic...
-
Feasibility of imaging synaptic density in the human spinal cord using [11C]UCB-J PET
PurposeNeuronal damage and synapse loss in the spinal cord (SC) have been implicated in spinal cord injury (SCI) and neurodegenerative disorders such...
-
Validation and test–retest repeatability performance of parametric methods for [11C]UCB-J PET
[ 11 C]UCB-J is a PET radioligand that binds to the presynaptic vesicle glycoprotein 2A. Therefore, [ 11 C]UCB-J PET may serve as an in vivo marker of...
-
Human biodistribution and dosimetry of [11C]-UCB-J, a PET radiotracer for imaging synaptic density
Rationale[ 11 C]-UCB-J is an emerging tool for the noninvasive measurement of synaptic vesicle density in vivo. Here, we report human biodistribution...
-
11C-UCB-J synaptic PET and multimodal imaging in dementia with Lewy bodies
ObjectiveDementia with Lewy bodies (DLB) is a common cause of dementia, but atrophy is mild compared to Alzheimer’s disease. We propose that DLB is...
-
Preclinical PET Studies of [11C]UCB-J Binding in Minipig Brain
PurposeLoss of neuronal synapse function is associated with a number of brain disorders. The [ 11 C]UCB-J positron emission tomography (PET) tracer...
-
Sapap3 deletion causes dynamic synaptic density abnormalities: a longitudinal [11C]UCB-J PET study in a model of obsessive–compulsive disorder-like behaviour
BackgroundCurrently, the evidence on synaptic abnormalities in neuropsychiatric disorders—including obsessive–compulsive disorder (OCD)—is emerging....
-
Human adult and adolescent biodistribution and dosimetry of the synaptic vesicle glycoprotein 2A radioligand 11C-UCB-J
AbstractThe ability to quantify synaptic density in vivo in human adults and adolescents is of vital importance to understanding neuropsychiatric...
-
Improved synthesis of SV2A targeting radiotracer [11C]UCB-J
Introduction[ 11 C]UCB-J is a tracer developed for PET (positron emission tomography) that has high affinity towards synaptic vesicle glycoprotein 2A...
-
Preliminary evidence for preserved synaptic density in late-life depression
Late-life depression has been consistently associated with lower gray matter volume, the origin of which remains largely unexplained. Recent in-vivo...
-
Effects of escitalopram on synaptic density in the healthy human brain: a randomized controlled trial
Selective serotonin reuptake inhibitors (SSRIs) are widely used for treating neuropsychiatric disorders. However, the exact mechanism of action and...
-
Synthesis and in vivo evaluation of [18F]UCB-J for PET imaging of synaptic vesicle glycoprotein 2A (SV2A)
PurposeSynaptic abnormalities have been implicated in a variety of neuropsychiatric disorders, including epilepsy, Alzheimer’s disease, and...
-
Validation of Parametric Methods for [11C]UCB-J PET Imaging Using Subcortical White Matter as Reference Tissue
PurposeThe aim of this study was to evaluate different non-invasive methods for generating (R)-1-((3-([ 11 C]methyl)pyridin-4-yl)methyl)-4-(3,4,5-trifl...
-
In vivo evidence of lower synaptic vesicle density in schizophrenia
Decreased synaptic spine density has been the most consistently reported postmortem finding in schizophrenia (SCZ). A recently developed in vivo...
-
The relationship between synaptic density marker SV2A, glutamate and N-acetyl aspartate levels in healthy volunteers and schizophrenia: a multimodal PET and magnetic resonance spectroscopy brain imaging study
Glutamatergic excitotoxicity is hypothesised to underlie synaptic loss in schizophrenia pathogenesis, but it is unknown whether synaptic markers are...
-
Spatial decrease of synaptic density in amnestic mild cognitive impairment follows the tau build-up pattern
Next to amyloid and tau, synaptic loss is a key pathological hallmark in Alzheimer’s disease, closely related to cognitive dysfunction and...
-
A metabolically stable PET tracer for imaging synaptic vesicle protein 2A: synthesis and preclinical characterization of [18F]SDM-16
PurposeTo quantify the synaptic vesicle glycoprotein 2A (SV2A) changes in the whole central nervous system (CNS) under pathophysiological conditions,...
-
Monitoring synaptic pathology in Alzheimer’s disease through fluid and PET imaging biomarkers: a comprehensive review and future perspectives
Alzheimer’s disease (AD) is currently constrained by limited clinical treatment options. The initial pathophysiological event, which can be traced...